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Background.Mycolic acids are a complex mixture of branched, long-chain fatty acids, representing key components of the highly
hydrophobic mycobacterial cell wall. Pathogenic mycobacteria carry mycolic acid sub-types that contain cyclopropane rings.
Double bonds at specific sites on mycolic acid precursors are modified by the action of cyclopropane mycolic acid synthases
(CMASs). The latter belong to a family of S-adenosyl-methionine-dependent methyl transferases, of which several have been well
studied in Mycobacterium tuberculosis, namely, MmaA1 through A4, PcaA and CmaA2. Cyclopropanated mycolic acids are key
factors participating in cell envelope permeability, host immunomodulation and persistence of M. tuberculosis. While several
antitubercular agents inhibit mycolic acid synthesis, to date, the CMASs have not been shown to be drug targets.Methodology/
Principle Findings. We have employed various complementary approaches to show that the antitubercular drug, thiacetazone
(TAC), and its chemical analogues, inhibit mycolic acid cyclopropanation. Dramatic changes in the content and ratio of mycolic
acids in the vaccine strain Mycobacterium bovis BCG, as well as in the related pathogenic species Mycobacterium marinum were
observed after treatment with the drugs. Combination of thin layer chromatography, mass spectrometry and Nuclear Magnetic
Resonance (NMR) analyses of mycolic acids purified from drug-treatedmycobacteria showed a significant loss of cyclopropanation
in both the a- and oxygenated mycolate sub-types. Additionally, High-Resolution Magic Angle Spinning (HR-MAS) NMR analyses
on whole cells was used to detect cell wall-associated mycolates and to quantify the cyclopropanation status of the cell envelope.
Further, overexpression of cmaA2, mmaA2 or pcaA in mycobacteria partially reversed the effects of TAC and its analogue on
mycolic acid cyclopropanation, suggesting that the drugs act directly on CMASs. Conclusions/Significance. This is a first report
on the mechanism of action of TAC, demonstrating the CMASs as its cellular targets in mycobacteria. The implications of this study
may be important for the design of alternative strategies for tuberculosis treatment.
Citation: Alahari A, Trivelli X, Gue´rardel Y, Dover LG, Besra GS, et al (2007) Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell
Wall Mycolic Acids in Mycobacteria. PLoS ONE 2(12): e1343. doi:10.1371/journal.pone.0001343
INTRODUCTION
A serious concern in antitubercular therapy is the emergence of
multi-drug resistant (MDR) strains, and more recently, extensively
drug-resistant (XDR) strains of Mycobacterium tuberculosis (M. tb) [1].
Strains of M. tb resistant to isoniazid and rifampicin, important
components in the first-line of drug treatment, are categorized as
MDR, while XDR strains of M. tb are defined as those that are also
resistant to at least three of the six classes of second-line drugs
(aminoglycosides, polypeptides, fluoroquinolones, thioamides, cyclo-
serine and p-aminosalicylic acid), which seriously limits treatment
options [2]. According to a recent WHO report, 10% of MDR cases
were XDR, across all geographical regions surveyed, thus posing the
threat of an untreatable global epidemic [3]. Therefore, the need for
rapid and continued progress in understanding the mechanism of
action of the current antitubercular agents and the discovery of new
cellular drug targets remain ever present.
Thiacetazone (TAC) is an inexpensive, antitubercular, bacte-
riostatic drug that has been widely used in combination with
isoniazid in Africa and South America [4]. Chemical analogues of
TAC, SRI-224 and SRI-286, have been synthesized and tested
against Mycobacterium avium and found to be more effective than
TAC in vitro and in mice [5]. We and others have recently shown
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that TAC is a prodrug that is activated by the mycobacterial
monooxygenase EthA, which is also the activator of two other
anti-tuberculosis drugs, ethionamide (ETH) and isoxyl (ISO)
[6,7,8]. However, the mechanism of action of TAC remains an
enigma. Our first observation on effects of TAC on M. bovis BCG
was that it affects mycolic acid synthesis [6].
Mycolic acids are very long chain, a-alkyl, b-hydroxy fatty acids
(Figure 1), covalently linked to arabinogalactan or trehalose in the
complex cell walls of bacteria of the Corynebacterium-Mycobacterium-
Nocardia group [9,10]. These lipids give rise to important
characteristics including resistance to chemical injury and dehydra-
tion, low permeability to antibiotics, virulence [11,12,13], acid-fast
staining [14] and the ability to persist within the host
[12,14,15,16,17]. Mycolic acids are also the targets of front-line
antitubercular drugs, such as isoniazid (INH) and ETH [18,19,20].
Mycolates from mycobacteria possess the longest carbon chains
consisting of the C56 meromycolate and the C26 a-branch. Their
synthesis is brought about by the co-ordinate activities of several
enzymes, involving numerous biochemical steps. During synthesis,
the meromycolate intermediate, which is interrupted by double
bonds at specific sites, may be modified by the action of different
cyclopropane mycolic acid synthases (CMASs) that convert double
bonds to cyclopropane rings. These modifications occur at the sites
of the two characteristic double bonds incorporated in the chain, the
proximal (closer to the b-hydroxy) or the distal double bond [9,10].
Enzymes of the CMAS family are S-adenosylmethionine-dependent
(SAM) methyltransferases, that share a high degree of sequence and
structural homology [21,22]. In M. tb, MmaA2 [23] and PcaA [12]
modify these double bonds to cis-cyclopropanes to produce a-
mycolates. Synthesis of both keto- and methoxy-mycolates involves
oxidation, methylation and cis- or trans-cyclopropanation by the
coordinate activities of the MmaA1 through MmaA4 and CmaA2
[9]. Differential action of the various CMASs leads to generation of a
repertoire of mycolic acid sub-types [22,24,25,26,27].
Molar ratios of the mycolic acid sub-types present in the
mycobacterial cell wall is species-dependent and has a profound
effect on the fluidity and permeability of the cell wall as well as the
immunological response in the host [11,12,28,29]. Mycolic acids
are either covalently attached to arabinogalactan or non-
covalently associated with the wall as complex glycolipids like
trehalose dimycolate (TDM), also called cord factor. While the
latter is an important immunomodulator in pathogenic mycobac-
teria, it has been recently shown that its proinflammatory capacity is
dependent on the nature of the constituent mycolic acids. For
example, TDM extracted from the cell envelope of a pcaA knock-out
mutant, was deficient in cis-cyclopropanated a-mycolic acids and was
shown to be hypoinflammatory [12]. The pcaA mutant was also
compromised in long-term survival in host mice. In sharp contrast, a
null mutant in the cmaA2 gene of M. tb that lacked trans-
cyclopropanated mycolates, was hypervirulent and the proinflam-
matory response was transferable through its TDM [29]. A mmaA4
knockout mutant that lacks keto- and methoxy-mycolates, showed
reduced cell wall permeability and was also attenuated in mice [11].
These reports illustrate the fact that enzymes of the CMAS family
are particularly relevant to virulence and persistence of M. tb.
In this study, we present a chemical library of twenty-three
analogues of TAC. Also, for the first time, a molecular target of
TAC and its chemical analogue SRI-224 is revealed. We have
analyzed the changes in mycolic acid profile in TAC-treated cells
of different mycobacterial species. An accumulation of uncyclo-
propanated mycolates was observed. This was further confirmed
by whole cell analyses, using a recently introduced application of
HR-MAS NMR. Further, strains independently overexpressing
cmaA2, mmaA2 or pcaA were constructed and found to be
significantly less affected by TAC or SRI-224 in their mycolate
profile. Thus, our results indicate that these drugs alter mycolic
acid biosynthesis by inhibiting cyclopropanation of the meromy-
colate chain. The lack of cyclopropanation of mycolates in drug-
treated mycobacteria is likely one of the reasons for the observed
effectiveness of the TAC in vivo. Nevertheless, presence of other
cellular targets of the drug, possibly, other SAM-dependent
enzymes, is not ruled out.
Figure 1. Structures and occurrence of mycolic acid sub-types in mycobacterial species presented in this study. * proximal position of
oxygenated mycolates is unsaturated [37].
doi:10.1371/journal.pone.0001343.g001
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METHODS
Mycobacterial strains and growth conditions
M. bovis BCG strain Pasteur, M. chelonae (ATCC 19536), and M.
marinum M strain were all grown either on Middlebrook 7H10 agar
supplemented with oleic acid-dextrose-catalase (OADC) enrich-
ment or in Sauton’s broth medium at 37uC or at 30uC for M.
marinum. Mycobacteria were transformed by electroporation and
recombinant clones were selected on 7H11 supplemented with
OADC and 25 mg/ml kanamycin.
Drug susceptibility testing of M. tuberculosis
TAC was purchased from Sigma (Saint Louis, MO), while SRI-
224 and other chemical analogues of TAC were synthesized at the
Southern Research Institute (Birmingham, AL). The chemical
synthesis of the analogues will be documented separately. A
primary screen was conducted by the BACTEC 460 radiometric
assay at an initial screening concentration of 12.5 mg/ml against
M. tbH37Rv (ATCC 27294) in BACTEC 12B medium as reported
[30]. Two samples (entries 11 and 16, Figure 2) were screened
against M. tb H37Rv in BACTEC 12B medium using the
Microplate Alamar Blue Assay (MABA) [30]. Drug stocks were
prepared in DMSO for dilution, and the stocks were filter
sterilized and stored at –70uC until usage. Compounds demon-
strating at least 90% inhibition in the primary screen were tested
again at lower concentrations in the BACTEC 460 system against
M. tb H37Rv to determine the minimum inhibitory concentration
(MIC). The MIC is defined as the lowest concentration effecting a
reduction in fluorescence of 99% relative to controls. For entry 11
in Figure 2, MIC90 was derived using the MABA assay. It has been
reported that the MABA MIC90 correlates well with a MIC99 for
the BACTEC 460 assay [30].
Plasmids and genetic manipulations
All cloning steps were performed in Escherichia coli TOP-10
(Invitrogen). M. tb H37Rv genomic DNA was used as a template
to amplify the coding regions of cmaA2, mmaA2 and pcaA using
either Vent DNA polymerase (New England Biolabs) or the
Phusion High-fidelity enzyme (Finnzymes). The following pairs of
primers were used: cmaA2-fwd 59-TGA CGT CAC AGG GCG
ACA CGA CAA GCG G-39, cmaA2-rev 59-GGA ATT CTT ATT
TGA CCA GAG TGA ACT GGC-39, mma2-fwd 59-TGG TCA
ACG ACC TAA CGC CGC AC-39, mmaA2-rev 59-GCG CAA
GCT TCT ACT TGC CAG CGT GAA CTG G-39, pcaA-fwd 59-
TGT CCG TGC AGC TCA CGC CGC-39, pcaA-rev 59-GGA
ATT CTT ACT TTT CCA GTG TGA ACT GGT CG-39. The
underlined sequences indicate the EcoRI or HindIII restriction sites
used in cloning the PCR products into plasmid pMV261 double-
digested with the same enzyme and MscI. This allowed the genes
to be expressed constitutively from the hsp60 promoter of the
vector [31]. All restriction enzymes were purchased from New
England Biolabs. All plasmid constructs were validated by DNA
sequencing (MWG Biotech).
Determination of the in vivo effects of TAC and
analogues on mycolic acid synthesis
The different mycobacterial strains were grown in Sauton’s medium
and treated with varying concentrations of TAC or its analogues as
discussed in the text. In vivo radiolabeling of lipids of was performed
with [1, 2-14C]-acetate (1 mCi/ml, 56 mCi/mmol, Amersham
Biosciences) for 8 h. Cells were harvested, subjected to alkaline
hydrolysis in tributyl-ammonium hydroxide as described previously
[6,33]. Methylesterification, extraction and resolution of mycolic
acids by either normal phase or argentation or 2-D thin layer
chromatography (TLC) was carried out as described previously
[6,33]. Briefly, equal radioactive amounts of each sample were
applied to a silica-coated aluminium TLC plate, which was
developed in different mixtures of solvents depending on the nature
of the TLC. TAC or SRI-224 solutions were added to the growth
medium at desired concentrations for a total period of 24 h, prior to
and including the 8 h of in vivo labeling period. In separate
experiments, L-[methyl-14C]-methionine (1 mCi/ml, 57 mCi/mmol,
Amersham Biosciences) was added to the cultures. For the
identification of mycolic acids covalently attached to the cell wall,
cells were first delipidated with chloroform/methanol (2:1) to remove
non-covalently attached lipids as reported earlier [33], followed by
methylesterification and extraction in diethyl ether. Mycolates were
finally dissolved in dichloromethane prior to TLC analysis.
Large-scale purification of the lipids X and Y
For structural analysis, mycobacterial lipids X and Y were purified
from 4L of M. bovis BCG shake-flask cultures, treated with 5 mg/ml
SRI-224 for 24 h [6]. Extraction of the mycolic acid methyl esters
(MAMEs) was carried out as described above. These were applied to
a column of silica coated with 50% solution of silver nitrate and
activated at 95uC, overnight. The MAMEs were eluted from the
column with a gradient of increasing concentrations of diethyl ether,
from 2% to 90%, in petroleum ether. The various fractions were
analyzed by argentation TLC. Lipids X and Y were identified by
their behavior on argentation TLC and verified by comparison with
radiolabeled mycolates extracted from drug-treated cells. Fractions
containing X and Y were applied to a preparative TLC plate
developed in petroleum ether:acetone (19:1, v/v) and the products
were scraped off the plate and resuspended in diethyl ether. The
solvent was then dried and the purified lipids resuspended in
dichloromethane. Purity was verified by argentation TLC.
Mass Spectrometry
Mass spectrometric analyses of the methyl esters of lipids X or Y
from M. bovis BCG, purified as above, were done on a Voyager
Elite reflectron MALDI-TOF mass spectrometer (PerSeptive
Biosystems, Framingham, MA, USA), equipped with a 337 nm
UV laser. Samples were solubilized in 1 ml chloroform/methanol
(2:1) and mixed on target with 1 ml of 2, 5-dihydroxybenzoic acid
matrix solution (10 mg/ml dissolved in chloroform/methanol 2:1).
NMR analyses
Lipids X or Y from M. bovis BCG, purified as described above,
were dissolved into deuterated chloroform containing 0.01% of
TMS and transferred into Shigemi tubes matched for D2O. Then
0.1 ml of deuterium oxide was added to avoid solvent evaporation
during long acquisition [34]. 1D proton NMR spectra were
recorded at 299K on a 800 MHz Avance II and 400 MHz Avance
Bruker spectrometers equipped with a 1H/13C/15N/2H and a
broad-band probes, respectively.
Whole cell analyses by HR-MAS NMR
M. bovis BCG cultures grown in Sauton’s medium were treated
with 1 mg/ml of either TAC or SRI-224 for 5 days. Cells were
harvested by centrifugation, heat-inactivated at 80uC for 20 min
and stored at 4uC till further use. For HR-MAS NMR analysis,
cell pellets were washed several times with deuterium oxide in
order to remove protonated water. Four mm Zr rotors (CortecNet,
France) were filled with 50 ml of cell pellets, centrifuged at low
speed and stirred with 5 ml of chloroform. Experiments were
recorded on a 800 MHz AvanceII Bruker spectrometer at 293K
Thiacetazone Inhibits CMASs
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with a 1H/13C/15N/2H probe spinning at 8 kHz. Uni-dimen-
sional selective COrrelation SpectroscopY (COSY) spectrum was
recorded with 1024 scans, a 5 ms Gaussian selective excitation on
the Ha resonance at 20.33 ppm and a 17.5 ms evolution delay.
RESULTS
Structure of TAC-related analogues and their
activity against M. tuberculosis
TAC has been widely used as a front-line therapeutic in poor
countries, since it is inexpensive [35]. This drug may prove useful
to treat patients infected with MDR strains, for whom the choice
of effective drugs is limited. TAC, a thiocarbamide-containing
drug, was chosen as a target pharmacophore for the preparation of
a second generation analogues (chemical synthesis will be
described elsewhere). We present here a library of 23 chemical
analogues of TAC, including SRI-286 and SRI-224 [5], which
have previously been shown to be active againstM. avium. We have
evaluated the potential of these drugs in inhibiting growth of M. tb
H37Rv. Drug susceptibility of M. tb by determination of the
minimal inhibitory concentration (MIC) of TAC and its analogues
was carried out using the BACTEC 460 radiometric method. As
Figure 2. Structures of chemical analogues of thiacetazone and their corresponding minimum inhibitory concentrations (MICs) in M. tb H37Rv.
MICs were determined by BACTEC 460 radiometric assay. *Data from MABA assay.
doi:10.1371/journal.pone.0001343.g002
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shown in Figure 2, several analogues exhibited potent antituber-
cular activity. Although this set represented modest diversity, a few
potential trends are notable. For example, three compounds (1, 2
and SRI-224) were found to be more active than the parent
molecule, suggesting that newer, more effective analogues might be
developed for clinical use. Entries 1–7 in Figure 2 show significant
activity (,1.0 mg/ml). These are all simple arylmethyl thiosemicar-
bazones where the aryl group is a phenyl, thiophene, or pyridyl
aromatic. The three most active compounds are 4-substituted phenyl
analogues as is TAC. The 4-pyridyl analogue 9 is the most active of
the pyridyl analogues (2-pyridyl, 15 or 3-pyridyl, 10), and this
analogue is, in many respects, similar to a 4-substituted phenyl
analogue. It is notable that a methyl substitution 3 can retain
significant activity relative to the des-methyl analogue 1, although
this trend is not without exception (7 versus 16). For the most part,
larger aryl groups attached to the thiosemicarbazone by different
distances/linkers results in compounds with reduced to little activity.
However, larger numbers of analogues will be required to develop a
robust structure-activity relationship for the thiosemicarbazone class
of antitubercular agents.
Inhibition of mycolic acid synthesis by TAC
We have recently reported that, following activation by the
monooxygenase EthA, TAC strongly alters the mycolic acid
profile of M. bovis BCG-treated cells [6]. Interestingly, this altered
profile was radically different from that after exposure of M. bovis
BCG to ISO, INH or ETH, all of which are antitubercular drugs
known to inhibit mycolic acid biosynthesis [6]. This study was
aimed at extending our previous observations to other mycobac-
terial species and includes chemical analogues of TAC in order to
identify the specific enzyme(s) of the mycolic acid pathway that are
inhibited by these thiocarbamide-containing drugs.
The effect of treatment of TAC or its chemical analogue, SRI-
224 (3 in Figure 2) on cell wall mycolates of M. bovis BCG strain
Pasteur was examined. Cells in the exponential phase of growth
were treated with increasing drug concentrations and labeled with
14C-acetate. Fatty acid methyl esters (FAMEs) and mycolic acid
methyl esters (MAMEs) were extracted, resolved by TLC and
visualized by autoradiography as described earlier [6]. Resolution
of the extracts by conventional TLC did not reveal major changes
in the mycolic acid profile after drug treatment (data not shown).
However, differences were apparent when the extracts were
resolved on TLC plates impregnated with silver nitrate. This
method of argentation TLC retards the migration of unsaturated
FAMEs and MAMEs [33]. Treatment of the cells with TAC or
SRI-224 led to a significant reduction in the synthesis of the a-
mycolates and to a lesser extent in that of the keto-mycolates, while
synthesis of oleic acid remained unaffected (Figure 3A). At TAC
concentrations between 1–5 mg/ml, accumulation of a product,
designated lipid X, was detectable. Treatment with SRI-224
produced an additional radiolabeled product, designated lipid Y.
Among the analogues, SRI-224 appeared to be the most effective
in terms of inhibition of mycolate synthesis. Although exposure to
SRI-286 (10 in Figure 2) was also accompanied by a clear
reduction in the synthesis of a- and keto-mycolates, this effect was
less dramatic than after exposure to TAC or in SRI-224 (data not
shown), consistent with the higher MIC value of SRI-286 against
M. bovis BCG strain Pasteur (MIC99=10–25 mg/ml for SRI-286,
0.25 mg/ml for SRI-224, 0.5 mg/ml for TAC, [6]). Inhibitory
effects on mycolic acid syntheses were observed even at SRI-224
concentrations lower than the MIC value (Figure 3B). These data
suggest that the level of mycolate inhibition, as observed on
argentation TLC, is directly correlated to the susceptibility of M.
bovis BCG towards the TAC analogues. Moreover, treatment with
the drug at low concentrations for a longer period of time, such as
5 days, accentuated these effects (Figure 3B).
Mycolates can either be covalently attached to arabinogalactan or
present as free lipids when associated with sugars such as trehalose
[9,10]. We investigated whether the accumulating lipids, X and Y
are attached to arabinogalactan or are present as extractable lipids
within the cell wall. Drug-treated or untreated control cells were
delipidated to remove lipid components that are non-covalently
attached to the cell wall and retain only those that are covalently
bound to arabinogalactan [33]. The lipids X and Y were still present
in the delipidated cells as seen in Figure 3C, suggesting that they are
covalently bound to the cell wall. Further, when resolved by two-
dimensional argentation TLC (Figure 3D), the accumulating
product X was found to migrate in the first dimension along with
the oxygenated keto-mycolates, and Y with the a-mycolates.
In vivo radiolabeling with 14C-acetate labels all sub-types of
mycolic acids. In contrast, labeling with [methyl-14C]-methionine
would reveal only those mycolates that involve S-adenosylmethio-
nine (SAM)-dependent methylation during their synthesis. Thus,
both, the a- and keto-mycolates are labeled due to the presence of
cyclopropane rings and additional methyl groups on the keto-
mycolates (Figure 1). Synthesis of the mycolates in the presence of
TAC or SRI-224, as visualized by labeling with [methyl-14C]-
methionine, indicated that the drug-induced product X is labeled,
but Y is not (Figure 3E). We therefore hypothesize that product Y is a
di-unsaturated lipid, devoid of cyclopropanes, while X likely carries a
methyl group. Taken together, these data suggest that X and Y are
unsaturated counterparts of the keto- and a-mycolates, respectively.
Structural determination of the drug-induced
mycolate precursors, X and Y
We reasoned that a detailed structural analysis of the two products
X and Y should help to determine which particular enzymatic step
of the mycolic acid biosynthetic pathway is inhibited by these
drugs. MAMEs were extracted from with either TAC- or SRI-
224-treated cells (5 mg/ml) for 24 h and X and Y were isolated as
described in Methods. Purity of the lipids was confirmed by
conventional TLC analysis (Figure 4A).
The structures of purified lipids X and Y were determined using
mass spectrometry (MS) and NMR spectroscopy. As shown in
Figure 4B, lipid X exhibits a MALDI-TOF-MS profile correspond-
ing to [M+Na]+ adducts of a family of C77 to C87 oxygenated
mycolates, in agreement with earlier studies [36]. Calculated
elemental compositions typify them as either keto-, epoxy- or v-1-
methoxymycolates. 1H-NMR analysis shows distinctive signals at d
2.41, 2.50 and 1.05 ppm attributed to -CH2(g) -CH(d) and -CH3(f)
associated with a keto-functional group, which establishes the nature
of X as a keto-mycolate precursor. However, it also indicates the
absence of both cis- and trans-cyclopropane rings, as the expected
characteristic upfield signals between d -0.5 and 0.7 ppm are missing
(Figure 4C). In addition, cis-ethylenic protons (a) and methylenic
protons (b) adjacent to cis-double bonds were observed at d 5.35 and
2.01 ppm, respectively, indicating that cyclopropane group is
replaced by a double bond. Accordingly, relative integrations of
specific signals associated with a double bond (a, b), keto group (f, d)
and methyl-esterified extremity of mycolate (c, e) indicate the
presence of a single keto group and a single double bond per
molecule. In contrast to lipid X, which appears to be a keto-mycolate
precursor, lipid Y showed a different MS profile, with similarities to a
family of C75 to C82 a-mycolates. As for X,
1H-NMR analysis of Y is
characterized by the absence of signals assigned to cis- and trans-
cyclopropane rings, and by the presence of intense cis-ethylenic
protons (a) and methylenic protons (b) adjacent to cis-double bonds at
Thiacetazone Inhibits CMASs
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d 5.35 and 2.01 ppm, respectively. Consistent with the MS data, no
signals associated with oxygenated functional group (keto, methoxy
or epoxy) were observed. Relative integrations of signals clearly
established the presence of two double bonds per molecule, thus
typifying Y as a di-uncyclopropanated a-mycolate. Structures of
TAC/SRI-224-induced lipids X and Y are represented in Figure 1.
TAC affects mycolic acid cyclopropanation in
different mycobacterial strains
The sub-types of mycolic acids and their relative ratios differ with
the mycobacterial strain [10]. We examined whether the drug-
induced inhibition of cyclopropanation in a- and keto-mycolates
with associated accumulation of unsaturated mycolate precursors
was species-specific. The responses of two other mycobacterial
strains, M. marinum and M. chelonae that produce different mycolic
acid sub-type combinations (Figure 1), to treatment with TAC or
SRI-224 were examined.
M. marinum, like M. tb, synthesizes three types of mycolates: the
dicyclopropanated a-, and the oxygenated keto- and methoxy-
mycolates (Figure 1) [37]. Unlike M. tb, the oxygenated mycolates
lack proximal trans-cyclopropanation. Treatment of M. marinum
cells with SRI-224 appeared to have a more dramatic effect on
mycolate synthesis as compared to TAC (Figure 5A). At higher
concentrations of SRI-224, the synthesis of the oxygenated
mycolates was severely diminished. Treatment with TAC led to
slight accumulation of an X-like product, while SRI-224 treatment
led to a strong accumulation of X-like and Y-like lipids.
The repertoire of mycolates of M. chelonae consists of an
unsaturated a’ and di-cyclopropanated a-mycolates along with their
unsaturated precursors bearing cis/cis or cis/trans double bonds [38].
As expected, after treatment with SRI-224 at 20 mg/ml, the
synthesis of a-mycolates was largely inhibited and was only
accompanied by the accumulation of an unsaturated product,
presumably lipid Y (Figure 5B). As observed in the other species, the
effect of TAC on a-mycolates was less intense than that of SRI-224 at
the same concentration.
Thus, all three mycobacterial species were similarly affected in
mycolic acid synthesis in the presence of TAC or SRI-224. The
drugs appear to inhibit mycolic acid synthesis, not during the fatty
acid elongation which is catalyzed by the type II fatty acid
synthase (FAS-II) [9,10], but rather at the later step of
Figure 3. Inhibition of mycolic acid biosynthesis in M. bovis BCG by treatment with TAC or its analogue SRI-224. Exponentially-growing cultures
were treated with the drugs for 18 h and labeled by adding 14C-acetate for another 8 h. Fatty acid methyl esters (FAMEs) and mycolic acid methyl
esters (MAMEs) were then extracted and separated by TLC on 10% silver nitrate-impregnated plates prior to exposure to a film overnight. All extracts
were loaded equally for 100,000 cpm on silica plates impregnated with 10% silver nitrate. The autoradiographs show FAMEs, MAMES, oleic acid
methyl esters (OAMEs), a- and keto-mycolates (k) and the lipids X and Y as indicated by arrowheads. (A) 1D TLC analysis using petroleum ether and
diethyl ether (17:3, v/v) as solvents. Drug concentrations employed are indicated in mg/ml. (B) 1D TLC profile of MAMEs extracted from cells treated
with low concentrations of SRI-224 for either 1 day or over a period of 5 days, as indicated. (C) Extracts prepared after delipidation of the cells to
remove the free and loosely bound lipids, while retaining the covalently bound mycolates. Extract from cells treated with SRI-224 but not subjected
to delipidation is included to identify the lipids X and Y by comparison with extracts from delipidated cells that were either untreated (c) or treated
with 5 mg/ml of the indicated drug for 24 h. (D) 2D TLC analysis on silica plates impregnated with 10% silver nitrate. Extracts were separated in the
first direction by using two developments with hexane/ethyl acetate (19:1, v/v) and in the second direction by using a triple development with
petroleum ether/diethylether (17:3, v/v). (E) Extracts from cells radiolabeled with [methyl-14C]-methionine are compared with those from cells
radiolabeled with 14C-acetate.
doi:10.1371/journal.pone.0001343.g003
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cyclopropanation, thus resulting in accumulation of unsaturated
mycolic acids.
In vivo quantification of cyclopropane rings in
whole cells
Relative quantification of mycolate cyclopropanation in whole
cells of mycobacteria was assessed by High-Resolution Magic
Angle Spinning (HR-MAS) Nuclear Magnetic Resonance (NMR).
This technique was previously shown to be effective for directly
demonstrating the effects of the antitubercular drug ethambutol on
the cell wall polysaccharides of living mycobacteria [39]. Here, for
the first time, we apply this method to observe modifications in the
structures of mycolic acids directly on whole cells of mycobacteria.
The 1H HR-MAS NMR spectrum of intact M. bovis BCG control
cells in D2O showed the presence of a well-isolated but excessively
broad signal, presumably resulting from the low diffusion rate of
mycolates within the cell wall, centred at 20.33 ppm (data not
shown). This was tentatively attributed to the upfield methylenic
proton of the cis-cyclopropyl ring according to standard purified
mycolates and literature [40]. As shown in Figure 6A, a well
resolved signal (Ha) was obtained after partial disruption of
mycobacterial cell wall by adding 5 ml of chloroform to cell pellets
directly into the Zr rotor. Attribution of spin system of cyclopropyl
ring was confirmed by irradiating Ha proton by a selective COSY
experiment. This permitted observation of Hb and Hc protons of
the cyclopropyl ring at d 0.56 and 0.64 ppm through 3J and 2J
connectivities with Ha, respectively (Figure 6B, C). Based on these
data, we used Ha proton as a probe for the relative quantification
of cyclopropanation by comparing its intensity in control and SRI-
224-treated cells of M. bovis BCG, after normalizing the spectra on
-CH2- signal at d1.25. As shown in Figure 6D, treatment of
cultures with 1 mg/ml of TAC or SRI-224 reduced the quantity of
cis-cyclopropane rings by ,75%.
Therefore, these data fully support and extend the conclusion that
the lipids X and Y are uncyclopropanated counterparts of the
oxygenated and a-mycolates, respectively. Interestingly, the structure
of these precursors is reminiscent of the mycolate precursors that
accumulate in M. tb mutant strains carrying a CMAS gene deletion,
such as in cmaA2 [41], pcaA [12] or mmaA2 [23].
Overproduction of CMAS in M. bovis BCG partially
reverses the effects of TAC
On the basis of the TLC and structural analyses of lipids which
accumulate in the presence of TAC or SRI-224, designated here
as X and Y, cyclopropanation appeared to be the site of action of
the drugs, in particular, cyclopropanation of the proximal double
bond. PcaA and CmaA2 have been shown to be responsible for
the cis- and trans-cyclopropanation of the proximal double bond in
a- and oxygenated mycolates, respectively [12,41]. MmaA2 has
been reported to catalyze cyclopropanation of the distal double
Figure 4. Structural determination of lipids X and Y. Lipids X and Y were purified from cell wall extract of M. bovis BCG Pasteur culture, following
treatment with SRI-224 (5 mg/ml) for 24 h. (A) Conventional TLC showing purity of the samples containing lipids X and Y, that were used for structural
analyses, as seen by staining with phosphomolybdic acid and charring. (B) m/z values from MALDI-TOF-MS spectra correspond to [M+Na]+ adducts of
a family of methylated keto-mycolates and a-mycolates for purified lipids X and Y, respectively. (C) For 1H-NMR analysis, protons are labelled (a to h)
according to their respective positions in functional groups. Relative integrations of protons have been normalized according to the number of
ethylenic protons (2 for X and 4 for Y) and are indicated in brackets. *stands for proton 1H signals of contaminant ethanol present in the NMR tubes.
doi:10.1371/journal.pone.0001343.g004
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bond in a-mycolates and cis-cyclopropanation of the proximal
double bond in the oxygenated mycolic acids [23]. If the
cyclopropanating activities of these enzymes is being inhibited
by TAC, then overproduction of the enzymes should reverse the
effects on mycolic acid profile. We tested this possibility by
independently overexpressing the cmaA2, mmaA2 or pcaA genes of
M. tb H37Rv both in M. bovis BCG and M. marinum.
The mycolic acid profiles of M. bovis BCG and M. marinum
overexpressing the selected CMAS genes were analyzed, with or
without treatment with 5 mg/ml of either TAC or SRI-224
(Figure 7). The effects were similar in both species. In general, cell
overproducing a CMAS enzyme were able to partially resist the
drug-induced changes in the mycolic acid profile. The amount of a-
mycolates produced under drug treatment in the recombinant
strains was detectably higher than in the control strain. More obvious
was the diminution of lipids X and Y, especially in the cmaA2-
overexpressing strain (Figure 7A). In the case of M. marinum
overexpressing either cmaA2 or pcaA, treatment with SRI-224 led
to a decrease in the X-like product and also an increase in the
synthesis of keto-mycolates (Figure 7B). In contrast, overexpression
of mmaA2 in this strain had the effect of reducing the amount of drug-
induced product X, but there was no detectable increase in keto-
mycolates. Thus, while overexpression of no single gene alone
permitted full recovery of mycolate synthesis in the presence of the
drugs, the accumulation of the lipids X and Y was distinctly reduced.
It is very likely, that full recovery of the mycolic acid profile in the
presence of the drug would require co-ordinate overexpression of all
the relevant CMAS genes at appropriate levels.
DISCUSSION
TAC is a widely used antituberculosis drug that forms a second-
line of therapy, often in conjunction with another drug, such as
INH [42]. Its use has been controversial due to the occurrence of
skin toxicity in HIV-positive individuals [43]. Chemical analogues
that may share the antimycobacterial activity of TAC without its
toxicity would be attractive in therapy. Based on MIC values of
the chemical analogues of TAC against M. tb H37Rv, several
promising candidate drugs from the series shown in Figure 2
appeared more potent than the parent molecule TAC. Of these,
SRI-224 and SRI-286 have earlier been shown to have potent
activity against different mycobacterial species both in vitro and in
vivo [5,6,44]. Treatment with drugs like INH, ETH, ISO or
thiolactomycin inhibits the fatty acid synthase, FAS-II, a
biosynthetic cycle contributing the early steps of mycolate
synthesis, thus effectively preventing synthesis of all mycolic acid
sub-types. TAC does not inhibit FAS-II activity but appears to act
at a later step. Once elongation of the fatty acid chain is achieved
by FAS-II, the meromycolates fail to be cyclopropanated in the
presence of TAC/SRI-224. Nevertheless, this does not prevent
them from being condensed with the a-chain via the polyketide
synthase Pks13 [45] and then covalently linked to sugars like
arabinogalactan. A result of TAC/SRI-224 treatment is thus,
accumulation of uncyclopropanated mycolic acids in the cell wall.
Whole cell analyses by HR-MAS NMR reveals structural
properties of surface-bound molecules. The signal indicating
presence of a proximal cis-cyclopropane is well-isolated in the
NMR spectrum and hence easily identifiable. Taking advantage of
this observation, we were able to conclusively demonstrate a
decrease in the cis-cyclopropane signal in drug-treated mycobac-
teria. Structural analyses of the unusual lipids, X and Y, which
accumulate in drug-treated cells confirmed absence of cyclopro-
panation in cell wall mycolic acids. Further, as observed by TLC
analyses, the mycolate profile could be partially recovered by
overexpression of cmaA2, mmaA2 or pcaA, singly. Thus, by following
complementary experimental approaches, we arrived at the same
conclusion that TAC and SRI-224 inhibit CMAS activities. A
direct proof employing an in vitro assay to monitor the activity of
the CMASs in the presence of TAC and its analogues is desirable,
but not available to date. This is essentially due to the lack of an
experimental ability to synthesize the meromycolyl-ACP sub-
strates, suitably unsaturated at specific sites. Moreover, to
demonstrate the effect of TAC on the CMAS activity in vitro, it
would be mandatory to supply TAC in its activated form, i.e., after
the action of the EthA monoxygenase. If a stable, activated form of
Figure 5. Inhibition of synthesis of cell wall mycolic acids in different mycobacterial species by treatment with TAC or its analogue SRI-224.
Autoradiogram of FAMEs and MAMEs extracted from exponentially growing cells that were radiolabeled in vivo with 14C-acetate. Drug concentrations
are indicated in mg/ml. The different mycolates are indicated by arrows. Mycolic acid profiles from M. marinum (A) and from M. chelonae (B). All other
details are as in Figure 3.
doi:10.1371/journal.pone.0001343.g005
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the drug could be made available in vitro, its co-crystallization with
a CMAS could also be envisaged.
Collation of current knowledge of CMAS enzymology and the
data presented here on the structures of mycolic acids synthesized
in the presence of TAC or its analogues, leads us to propose a
model for the action of these drugs. A simplified schematic shown
in Figure 8A illustrates generation of the mycolic acid sub-types in
M. bovis BCG as a result of action of different CMAS enzymes.
Lipid Y, which is unsaturated at the distal and proximal positions,
can be regarded as a common precursor for generation of both a-
and keto-mycolates, and could serve as a substrate for both
MmaA2 and MmaA4. MmaA2 would introduce a distal cis-
cyclopropane and thus commit Y to the a-mycolic acid branch of
synthesis, while action of MmaA4 would initiate synthesis of the
oxygenated lipid X, committing it to keto-mycolate synthesis
[23,46]. Next, PcaA or CmaA2 would introduce the proximal
cyclopropane rings [12,41], generating either the a- or keto-
mycolates, respectively. From the structural analysis of the lipids X
and Y, it appears that the CMASs are differentially inhibited by
TAC or SRI-224. According to our model (Figure 8B), MmaA2 is
most strongly inhibited by TAC, while MmaA4 is largely
unaffected. We speculate that in TAC-treated cells, owing to the
Figure 6. In vivo identification and relative quantification of cis-cyclopropanes by 1H HR-MAS NMR. (A) Detail of 1H HR-MAS spectrum of control
whole cells of M. bovis BCG. (B) Unidimensional selective COSY spectrum after irradiation of Ha signal showing 3J and 2J connectivities of cis-
cyclopropyl ring Hb and Hc protons to Ha as depicted in (C). (D) Relative quantification by 1H HR-MAS NMR of cis-cyclopropanes based on differential
integration of the Ha signals in control untreated cells (c) or cells treated with TAC-treated (1 mg/ml) (TAC) or SRI-224-treated (1 mg/ml) (224). Results
are representative of two independent experiments.
doi:10.1371/journal.pone.0001343.g006
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Figure 7. Partial recovery of mycolic acid synthesis in the presence of TAC or SRI-224 in strains overexpressing the CMAS genes. Autoradiogram
of FAMEs and MAMEs extracted from exponentially growing cells that were radiolabeled in vivo with 14C-acetate. (A) M. bovis BCG or (B) M. marinum
containing the plasmid vector pMV261 or the same vector carrying cmaA2, mmaA2 or pcaA of M. tb H37Rv. Extracts were obtained from untreated
control cells (c) or cells treated with 5 mg/ml of either TAC or SRI-224 as indicated. All other details are as in Figure 3.
doi:10.1371/journal.pone.0001343.g007
Figure 8. Proposed mechanism for generation of mycolic acid sub-types by the action of CMAS enzymes (A) and inhibition by TAC/SRI-224 (B).
The generation of a- and the oxygenated mycolic acids is considered to follow to two independent pathways. A common, di-unsaturated precursor,
Y, is envisaged for the two pathways. Y is subsequently transformed into a-mycolic acids by the action of the MmaA2 and PcaA that modify the distal
or proximal double bond, respectively. Action of MmaA4 commits Y to the pathway for the oxygenated mycolic acids, by producing the precursor X.
MmaA3, which is required for generation of methoxy-mycolic acids in M. tb is inactive in M. bovis BCG Pasteur due to the presence of a point
mutation [50]. The proximal double bond is modified by the CmaA2 (and MmaA2) or PcaA to generate trans- or cis-cyclopropanated derivatives,
respectively. In the presence of TAC, all the CMASs mentioned above are inhibited, except for MmaA4. Due to inhibition of MmaA2, excess of Y is
diverted to MmaA4 leading to generation of X, which accumulates due to lack of activities of CmaA2 and MmaA2. SRI-224 appears to affect MmaA4
to a certain degree, leading to accumulation Y in addition to X. (For simplicity, only the meromycolyl moiety of mycolates has been depicted).
doi:10.1371/journal.pone.0001343.g008
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inhibition of MmaA2 activity, the initial excess of common
precursor Y would be shunted to serve as a substrate for MmaA4
resulting in synthesis of X, which accumulates due to lack of
activity of CmaA2 and MmaA2. Thus, treatment with TAC led to
a more significant reduction in the content of a-mycolates
compared to the keto-mycolates with concomitant build-up of
X. A similar but opposite situation has been reported in a MmaA4
knock-out mutant [46], wherein the Y is shunted to serve as a
substrate for MmaA2 instead, leading to lack of oxygenated
mycolates with concomitant accumulation of precursors of a-
mycolates. Treatment with SRI-224 appears to inhibit MmaA4 as
well as the other CMASs, leading to accumulation of the precursor
Y. Thus, despite their high degree of structural homology [21,47],
the CMASs show differential sensitivity to TAC and SRI-224,
resulting in abnormal ratios of mycolates.
While our data points overwhelmingly to the inhibition of the
CMASs by TAC or SRI-224, overexpression of the CMAS genes
as described here was unable to significantly alter the MICs
against the drugs (data not shown). Moreover, in other growth
experiments, we observed a significant inhibition of cyclopropana-
tion at low concentrations (0.025 mg/ml, ten times lower than the
MIC value) without any significant effect on growth in culture
(data not shown). This is consistent with the reports that in vitro
growth of M. tb mutants in cmaA2, pcaA, mmaA2 or mmaA4 was
largely unaffected, although the virulence of these was compro-
mised in mice and macrophage cell lines [11,12,17]. Thus, while
the CMASs enzymes show extreme sensitivity to TAC, the lack of
cyclopropanated mycolic acids may not be the basis for the growth
inhibition in vitro, pointing to the existence of additional drug
target(s) responsible for the observed bacteriostasis. The success of
TAC as an antitubercular drug might, therefore, be attributed to
the likely effects on an unknown target(s) as well as to the
consequences of inhibition of CMAS activities in vivo. It is also
possible that the simultaneous inhibition of several members of the
CMAS family by TAC as seen in this study, has a more
pronounced effect on growth in vivo than that caused by the lack of
an individual CMAS enzyme through mutation as described by
the earlier reports [11,12,17]. To resolve the matter, we are
currently pursuing a mutagenesis approach to screen for TAC-
resistant mutants. The aim is to uncover a strain that would be
drug-resistant due to a mutation influencing the alternate target,
while still being affected in mycolic acid cyclopropanation like the
parent strain. The effect of the drug on mycolates would thus be
uncoupled from the effects leading to the bacteriostatic effect in
vitro. We have isolated a few spontaneous drug-resistant mutants
for both TAC and SRI-224, which are currently being analyzed in
terms of their mycolate profile, cell wall permeability and
immunopathogenicity.
Molar ratios of the mycolic acid sub-types profoundly affect
fluidity and permeability of the cell wall, as well as the
immunological response in the host [11,12,28,29]. Together,
these observations favor the idea of CMAS family being important
in virulence and persistence in pathogenic mycobacteria. The
absence of cyclopropanated lipids in mammals emphasizes
CMASs as attractive drug targets. The presence of persistent
bacteria is considered to be the major reason for a lengthy therapy
[48]. Therefore, genes such as pcaA have been proposed to be
attractive target for the development of drugs against persistent
bacilli [49]. However, all studies reported so far demonstrate the
effects of knock-out of a single CMAS gene at a time, unlike the
effect of the drugs described here that are inhibitory to practically
the entire family of CMASs, all at the same time. In addition, the
structural similarity of these enzymes [21,47] suggests the
possibility that one inhibitor may be effective against multiple
targets, reducing the potential for drug resistance, particularly
desirable for any new drug in the fight against tuberculosis. In this
context, among the second generation TAC analogues described
here, those with increased potency may be evaluated for desirable
pharmacokinetic properties. Overall, our study presents for the
first time a mechanism of action of TAC that could at least
partially explain its effectiveness in the field. It likely provides a
foundation for rational drug design, which may lead to the
development of a novel class of inhibitors targeting the CMAS
family of enzymes.
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